Navigation Links
MannKind Submits NDA for AFRESA for Treatment of Diabetes
Date:3/16/2009

VALENCIA, Calif., March 16 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of AFRESA(R) (insulin monomer human [rDNA origin]) Inhalation Powder and the AFRESA(R) Inhaler for the treatment of adults with type 1 or type 2 diabetes mellitus for the control of hyperglycemia.

There are 23.6 million people in the United States, or 8% of the population, who have diabetes. Diabetes currently affects 246 million people worldwide and is expected to affect 380 million by 2025. Each year, a further 7 million people develop diabetes and 3.8 million people succumb to the disease.

AFRESA is an ultra rapid-acting insulin. It is a drug-device combination product, consisting of AFRESA Inhalation Powder pre-metered into single unit dose cartridges and the AFRESA Inhaler as the delivery device for oral inhalation. However, the feature that distinguishes AFRESA from all other insulin products is not the route of administration - it is the pharmacokinetic profile. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. AFRESA achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent or impaired in patients with diabetes.

The NDA submission is based on an extensive clinical program, involving 44 completed studies and five ongoing studies at the time of submission. The clinical program included over 5,300 patients. More than 2,450 subjects with type 1 or type 2 diabetes were randomly assig
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
2. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
3. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
4. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
5. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
6. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
7. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
8. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
9. MannKind to Present at the UBS Global Life Sciences Conference
10. MannKind Corporation Reports Second Quarter Financial Results
11. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Neurocrine ... that Kevin Gorman , President and Chief Executive ... Barclays Global Healthcare Conference in Miami.   ... at 10:15am ET (7:15am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
(Date:3/3/2015)... BlueInGreen announces the ... sales network. The business venture will bring the ... Atlantic Provinces, exclusively through Resource Systems. , Since ... Canada’s premiere manufacturing representative firms, hosting a diverse ... and wastewater markets. More information on Resource Systems ...
(Date:3/3/2015)... NEW YORK , March 3, 2015 ... that Jeffrey I.D. Lewis has joined the ... Practice, resident in the New York ... also handles trademark matters, as well as other intellectual ... registered patent attorney, Mr. Lewis represents both plaintiffs and ...
(Date:3/3/2015)... , March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... the scientific journal, Expert Opinion on Biological Therapy ... Dr. Zhenggang Zhang , at the Henry Ford ... that Thymosin beta 4 (TB4) has the capacity to ... hours or more post-injury, leading to neurological recovery in ...
Breaking Biology Technology:BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... condition of esophagus eliminated in 90 percent ... ... BARRX Medical, Inc., the,global technology leader for treating precancerous conditions of ... a,multi-center U.S. study were free of the highest-risk of Barrett,s,esophagus after ...
... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that ... Annual Global Healthcare Conference on,May 19, 2008 at 4:55 ... 2008 UBS,Global Generic and Specialty Pharmaceuticals Conference on Thursday, ... EDT). The presentations will,be web cast live and may ...
... Escalon Medical Corp.,(Nasdaq: ESMC ) today announced ... March 31, 2008., For the third quarter of ... $6,900,000 reported in the same period last fiscal,year. Product ... the,Company,s business units., Net revenue for the third ...
Cached Biology Technology:New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 2New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 3Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 2Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 2Escalon(R) Reports Third Quarter Fiscal 2008 Results 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 4Escalon(R) Reports Third Quarter Fiscal 2008 Results 5Escalon(R) Reports Third Quarter Fiscal 2008 Results 6Escalon(R) Reports Third Quarter Fiscal 2008 Results 7Escalon(R) Reports Third Quarter Fiscal 2008 Results 8
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 27, 2015   Marvin Test Solutions ... innovative test solutions for military, aerospace, and ... its TS-323 GENASYS Test Platform ... GENASYS is a high-performance PXI-based system designed ... that require performance functional testing. GENASYS features ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... It,s long been known that alcohol use in ... birth defects, but researchers who study fetal alcohol syndrome ... disorder, detecting it early, or effectively treating it, say ... the issue of Developmental Neuroscience , four first-year ...
... How do we begin to understand what early life was ... planet shifted from an oxygen-free and probably ice-covered realm to ... who decodes the early record of life on Earth has ... a significantly clearer picture of this dynamic environment. Alison Olcott ...
... , THE WOODLANDS, Texas , June 15 ... company focused on discovering breakthrough treatments for human disease, announced today ... clinical trial of LX4211 for patients with type 2 ... June 19 – 22, 2010 in San Diego, ...
Cached Biology News:Little is understood about alcohol's effect on fetal development, Georgetown researchers say 2Little is understood about alcohol's effect on fetal development, Georgetown researchers say 3Delineating primary and secondary organic carbon in neoproterozoic glacial sediments 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 3Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 4Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 5
... hormones which belong to the transforming ... superfamily is a large group of ... aspects of development, reproductive function and ... TGF-s, bone morphogenetic proteins, growth differentiation ...
... Beads Sterile plating in just seconds ... and potentially hazardous ethanol flaming, More uniform ... ready-to-use sterile packaging: dispenser bottle for spreading 100 ... Fastest and easiest way to spread cells ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... laboratories working in a regulated environment, ... pipette calibration software that automates gravimetric ... a framework that meets todays regulatory ... a secure solution that includes a ...
Biology Products: